stockrowJohnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Net income
Johnson & Johnson's net income for fiscal 2025 was $26.8B, up 90.6% from $14.1B in fiscal 2024. Over the twelve months to 30 September 2026 it was $16.1B. Over the past ten years it has ranged from $1.3B (fiscal 2017) to $35.2B (fiscal 2023); the current reading is higher than 91% of that period. Johnson & Johnson ranks 3rd of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $26.8B | 90.56% |
| FY2024 | $14.1B | (59.99%) |
| FY2023 | $35.2B | 95.94% |
| FY2022 | $17.9B | (14.07%) |
| FY2021 | $20.9B | 41.89% |
| FY2020 | $14.7B | (2.68%) |
| FY2019 | $15.1B | (1.16%) |
| FY2018 | $15.3B | 1,076.69% |
| FY2017 | $1.3B | (92.14%) |
| FY2016 | $16.5B | 7.34% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $210.0M | (96.21%) |
| Jun 2026 | $5.5B | 5.71% |
| Mar 2026 | $5.2B | 2.33% |
| Dec 2025 | $5.1B | (0.70%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| LLY Eli Lilly and Company compare | $27.6B |
| JNJ Johnson & Johnson | $16.1B |
| AZN AstraZeneca PLC compare | $13.3B |
| ABBV AbbVie Inc. compare | $10.3B |
| NVS Novartis AG compare | $10.0B |
| AMGN Amgen Inc. compare | $9.4B |
| PFE Pfizer Inc. compare | $4.1B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on JNJ
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement